Log in
Log in
Or log in with
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
Twitter Twitter
Facebook Facebook
Apple Apple     


Delayed Nyse  -  04:03 2022-12-02 pm EST
110.04 USD   +0.22%
12/02Merck Could Retain Keytruda Patent With New Formulation
12/02Compass Therapeutics, Inc. - a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases
12/01Sector Update: Healthcare Stocks Ending Slightly Higher
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

TILT Biotherapeutics Collaborates with MSD on Immunotherapy Clinical Trial in Checkpoint Inhibitor Refractory Non-Small Cell Lung Cancer

09/27/2022 | 10:01am EST

Finland - TILT Biotherapeutics, a clinical-stage biotechnology company developing cancer immunotherapies, announces it has signed a second clinical trial collaboration and supply agreement with MSD, a tradename of Merck & Co., Inc., Rahway, NJ, USA, for a new clinical trial evaluating TILT-123, its oncolytic adenovirus armed with two human cytokines, in combination with KEYTRUDA (pembrolizumab), MSD's anti-PD-1 therapy.

This Phase I, open label, dose escalation trial will include 12 to 24 patients with immune checkpoint inhibitor refractory non-small cell lung cancer (NSCLC). This latest trial builds on the company's emerging data on the use of its oncolytic immunotherapy candidate TILT-123 currently in trials for several other indications where promising results of intravenous usability has motivated the expansion of the portfolio of trials.

TILT Biotherapeutics' CEO, Akseli Hemminki, a cancer clinician who has personally treated hundreds of cancer patients, said, 'We already have clinical trials running in Europe and the USA in several cancer types, including ovarian cancer, head and neck cancer, and melanoma. We are planning several more, one of which is this new collaboration in NSCLC with our collaborator MSD. Overall, our armed oncolytic viruses are showing potential in the clinic to increase the anti-tumor benefits of checkpoint inhibitors for a range of cancers where there is a pressing need for better therapies.' The heart of TILT's innovative approach revolves around the use of armed oncolytic adenoviruses, using cytokines and other molecules to boost the patient's T-cell immune response to better enable it to find and destroy cancer cells.


Aino Kalervo

Tel: +447789435990

Email: aino@tiltbio.com

About TILT Biotherapeutics

TILT Biotherapeutics is a clinical-stage biotechnology company developing cancer therapeutics based on its proprietary oncolytic adenoviruses armed with molecules including cytokines that can stimulate, or suppress, T cells. The company's patented TILT technology, which can be delivered locally and systemically, modifies the tumor microenvironment, and eliminates its ability to suppress immune responses to cancer, thereby enhancing T-cell therapies such as immune checkpoint inhibitors, tumor infiltrating lymphocyte (TIL) therapy, and CAR T therapies. TILT's lead asset, TILT-123, is a 5/3 chimeric serotype adenovirus armed with two human cytokines: TNF alpha and IL-2. TILT-123 has demonstrated a 100% response rate in pre-clinical cancer models in vivo, and it is currently in Phase 1 clinical trials.

The Company's pioneering approach has been recognized by industry leaders including with the Merck KGaA and Pfizer Alliance, who are collaborating to investigate TILT-123's therapeutic effect in combination with the PD-L1 inhibitor, Avelumab (Bavencio), in Head and Neck cancer (NCT05222932). The Company also has a collaboration with MSD, a tradename of Merck & Co., Inc., Rahway, NJ, USA, investigating TILT-123 in combination with pembrolizumab (KEYTRUDA) in Ovarian Cancer (NCT05271318). In 2019, TILT established an additional partnership with Biotheus, a privately held Chinese company based in Zhuhai, Guangdong, China, for the development and commercialization of TILT's proprietary oncolytic virus TILT-123 in Greater China. Based in Helsinki, Finland, the company was established in 2013 as a spin-out from the University of Helsinki. It has funding from Lifeline Ventures, Finnish Industry Investment (TESI), angel investors, Business Finland, and the European Innovation Council (EIC).

(C) 2022 Electronic News Publishing, source ENP Newswire

All news about MERCK & CO., INC.
12/02Merck Could Retain Keytruda Patent With New Formulation
12/02Compass Therapeutics, Inc. - a clinical-stage, oncology-focused biopharmaceutical compa..
12/01Sector Update: Healthcare Stocks Ending Slightly Higher
12/01Compass Therapeutics Doses First Patient in Trial of its CTX-471 Immunotherapy Combined..
12/01Transcript : Merck & Co., Inc. Presents at 5th Annual Evercore ISI HealthCONx..
12/01First Wave BioPharma Files IND For Enhanced Formulation Of Adrulipase; Topline Results ..
12/01Merck to Present Data From Its Hematology Portfolio and Promising Pipeline at the 64th ..
11/29Merck Declares Quarterly Dividend of $0.73 Per Share; Payable Jan. 9 to Shareholders of..
11/29Merck Announces First-Quarter 2023 Dividend
11/29Merck & Co., Inc. Announces Dividend for the First Quarter of 2023, Payable on January ..
More news
Analyst Recommendations on MERCK & CO., INC.
More recommendations
Financials (USD)
Sales 2022 59 072 M - -
Net income 2022 14 812 M - -
Net Debt 2022 18 689 M - -
P/E ratio 2022 18,9x
Yield 2022 2,54%
Capitalization 279 B 279 B -
EV / Sales 2022 5,04x
EV / Sales 2023 4,97x
Nbr of Employees 67 500
Free-Float 70,8%
Chart MERCK & CO., INC.
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MERCK & CO., INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 26
Last Close Price 110,04 $
Average target price 109,61 $
Spread / Average Target -0,39%
EPS Revisions
Managers and Directors
Robert M. Davis President, Chief Executive Officer & Director
Caroline A. Litchfield Chief Financial Officer & Executive Vice President
Kenneth C. Frazier Executive Chairman
Dave Williams EVP, Chief Information & Digital Officer
Lisa LeCointe-Cephas Chief Ethics & Compliance Officer, SVP
Sector and Competitors
1st jan.Capi. (M$)
MERCK & CO., INC.43.58%278 995
JOHNSON & JOHNSON4.57%467 679
ABBVIE INC.20.87%289 331
NOVO NORDISK A/S22.04%285 887
PFIZER, INC.-13.50%285 774